PENNVAX®-GP is a developmental vaccine to prevent and treat HIV strains primarily present in Africa, Asia, Europe, and North America. It is intended to induce broad antibody and T-cell immune responses. This multi-subtype vaccine is based on optimized synthetic immunogens targeting two env antigens as well as gag and pol antigens—providing global coverage against HIV-1 subtypes. It is delivered using Inovio’s CELLECTRA® electroporation device. PENNVAX-GP is our lead preventive and therapeutic HIV DNA vaccine candidate. A phase I study is currently being conducted in collaboration with the HIV Vaccine Trials Network (HVTN).
Inovio’s PENNVAX-GP HIV vaccine is also being tested in combination with other novel DNA vaccine constructs encoding for new HIV envelope proteins in a five year preclinical program. Preclinical studies are being funded by the National Institute of Allergy and Infectious Diseases (NIAID).